Posted by AGORACOM-JC
at 7:51 AM on Friday, January 22nd, 2021
Announced that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. and the shareholders of Concierge effective January 19, 2021 to acquire 100% of Concierge’s issued and outstanding securities
Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.
Toronto, Ontario–(January 22, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. (“Concierge“) and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“) to acquire 100% of Concierge’s issued and outstanding securities (the “Transaction“). Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.
“Health care is on the verge of a revolution, one that will be driven by A.I. technologies. Medical services are already strained by the growing demand for healthcare worldwide. By leveraging A.I. technologies, medical we will be able to provide services more quickly and accurately,” said Marshall Gunter, CEO of Datametrex.
Posted by AGORACOM-JC
at 7:47 AM on Friday, January 22nd, 2021
Company has been selected by bdG Sports to provide its complete venue management platform to the Paiute Las Vegas Championship, a Korn Ferry Tour event, which will be played April 12-18, 2021 at the Las Vegas Paiute Golf Resort.
Korn Ferry Tour is the developmental tour for the U.S.-based PGA Tour and features professional golfers who have either not yet reached the PGA Tour, or who have done so but then failed to win enough FedEx Cup points to stay at that level
VANCOUVER, British Columbia, Jan. 22, 2021 — Loop Insights Inc. (MTRX:TSXV OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the Company has been selected by bdG Sports to provide its complete venue management platform to the Paiute Las Vegas Championship, a Korn Ferry Tour event, which will be played April 12-18, 2021 at the Las Vegas Paiute Golf Resort.
KORN FERRY FEATURES OVER 20 TOURNAMENTS IN 2021 AS DEVELOPMENT TOUR FOR PGA TOUR
The Korn Ferry Tour is the developmental tour for the U.S.-based PGA Tour and features professional golfers who have either not yet reached the PGA Tour, or who have done so but then failed to win enough FedEx Cup points to stay at that level. Since the 2013 season, the Korn Ferry Tour has been the primary pathway for those seeking to earn their PGA Tour card.
The tournament will have a full field of 156 players who will compete for a $600,000 purse. More importantly, participants will be competing in a season-long points race with the Top 25 finishers of the regular season earning PGA TOUR cards for the 2021-22 season. Local members of the Tour include Harry Hall, David Lipsky, Taylor Montgomery, and John Oda.
The implementation of Loop’s venue management platform at the Paiute Las Vegas Championship is another significant vote of confidence from the professional sports world following the successful deployment of our venue management platform at multiple live events.
Posted by AGORACOM-JC
at 6:53 PM on Thursday, January 21st, 2021
Today’s press release from HPQ might have been a little technical for newcomers but the words from CEO Bernard Tourillon explain exactly how important it was:
“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications ….. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Moreover, Tourillon couldn’t help but display his feelings and proclaimed this was going to be a fun year for HPQ.
Posted by AGORACOM-JC
at 12:46 PM on Thursday, January 21st, 2021
Announced that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents 17,810,000 Special Warrants of the Company on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 for total gross proceeds of up to $6,500,650
Each Special Warrant shall be automatically exercisable into units of the Company, as described below. Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant
VANCOUVER, British Columbia, Jan. 21, 2021 — Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“ Hollister ” or the “ Company ”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has now agreed to offer for sale, together with a syndicate of agents (together with Eight Capital, the “ Agents ”), 17,810,000 Special Warrants of the Company (the “ Special Warrants ”), on a “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $0.365 (the “ Issue Price ”) for total gross proceeds of up to $6,500,650 (the “ Offering ”).
Each Special Warrant shall be automatically exercisable into units of the Company (the “ Units ”), as described below. Each Unit shall consist of one common share of the Company (a “ Share ”) and one-half of one common share purchase warrant (each full warrant, a “ Warrant ”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $0.50 per Share for a period of 46 months following the Closing Date.
Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “ Automatic Exercise Date ”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “ Securities Commissions ”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “ Qualifying Prospectus ”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “ Qualifying Supplement ”), and (ii) the date that is four months and one day after the Closing of the Offering.
Posted by AGORACOM-JC
at 9:38 AM on Thursday, January 21st, 2021
Q3 2020 Financial Highlights:
Revenue increased by more than 100% in Q3 2020, in comparison to Q3 2019.
A combined $3.12 Million raised through private placement subscriptions with strategic investors.
January 21, 2021 – Toronto – Binovi Technologies Corp. (Binovi) (TSXV:VISN ) I ( OTC:BNVIF ) | ( GR:2EYA ) a leader in neuro-vision performance technology, reports results for the Company’s fiscal third quarter, ended November 30, 2020. The Company’s net sales results continue to be affected by the global health crisis. Increased demand for products across multiple categories led to an increase in top-line and gross margin results.
“Strategically positioned within telehealth, we believe the coming quarters will be pivotal in establishing our reputation and status as a competitor within this rapidly growing marketplace. While we are seeing strong growth across the business, it is important to recognize that we are making big investments in our people and infrastructure that are essential to support the significant growth that lies ahead. This includes big investments in our telehealth SaaS, our provider network, and personnel are critical as we scale the business,” stated Executive Chairman, Terry Booth.
Q3 2020 Financial Highlights:
Revenue increased by more than 100% in Q3 2020, in comparison to Q3 2019.
A combined $3.12 Million raised through private placement subscriptions with strategic investors.
Operational Highlights:
Since the launch of Binovi, more than 800 organizations have been registered and have used the platform for vision therapy and/or sports vision performance. These organizations have created nearly 31,000 users, together completing more than 400,000 active sessions centered around the Binovi Library list of activities, custom activities created by our member organizations.
Advanced the development of the company’s web-based telehealth SaaS, Binovi Connect. The beta launch of the platform is planned for Q1 2021.
Product marketing continues to grow brand awareness and promote sales, with an increase of 300% in website traffic, with improvements in direct media marketing and general top-of-mind awareness.
Posted by AGORACOM-JC
at 9:26 AM on Thursday, January 21st, 2021
Selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc.
Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.
Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms.
Los Angeles, CA, Jan. 21, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced it has been selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc. (“ILS”)
Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.
Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms. The main use case of the launch system is public disturbance management for military and public safety organizations.
“ILS approached Draganfly for this project because we are extremely impressed with their innovation in engineering,” said Greg Sullivan, CEO, Integrated Launcher Solutions. “Our client base requires North American developed and made solutions. Draganfly has the expertise to get this project executed.”
“We are honored at the confidence that Integrated Launcher Solutions has placed with Draganfly in overseeing the development of this very important drone technology,” said Cameron Chell, CEO Draganfly. “I am confident that the Draganfly team will provide the right set of expertise and management to develop the non-lethal ILS Air support Defense System.”
Posted by AGORACOM-JC
at 8:18 AM on Thursday, January 21st, 2021
Low-Cost Manufacturing of Nano Silicon Materials
Gen1 NSiR system performance exceeded design and modelling expectations: • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires. • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
MONTREAL, Jan. 21, 2021 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), through its wholly – owned subsidiary, HPQ Nano Silicon Powders inc (“HPQ NANO”), is pleased to update shareholders on milestones achieved during ongoing Gen1PUREVAPTMNano Silicon Reactor (“NSiR”) commissioning tests conducted by technology provider PyroGenesis Canada Inc. ( TSX: PYR ) .
“With the Gen1 PUREVAPTMNSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications, as we continue working on scaling up the capabilities of our PUREVAPTMNSiR process.” said Bernard Tourillon, President and CEO HPQ Silicon.
PUREVAPTMNSiRLOW-COST PROCESS: FIRST RESULTS ENCOURAGING, MORE TESTING TO FOLLOW
The material produced, under the less than optimum operating conditions of the first commissioning tests, was analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD) and yielded the following information:
Gen1 NSiR system performance exceeded design and modelling expectations: • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires. • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.
SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
Samples from these commissioning tests have been sent to Professor Lionel ROUÉ of the CentreÉnergieMatériauxTélécommunications (EMT) for electro-chemical evaluation.
Using results from data collected during these preliminary tests, PyroGenesis technical team has improved the design of the system and the operational parameters of the reactor. • It will be possible to provide further inputs and controls on the process to customize the composition and size of the spherical nano powders and nano wires.
The Gen1 NSiR is now ready to commence further testing of Silicon nano materials under new conditions, with a goal of producing larger size Silicon (Si) nanopowders and nanowires.
A METHODICAL APPROACH TO THE COMMERCIAL DEVELOPMENT OF OUR DISRUPTIVE TECHNOLOGY
Despite massive investment in Silicon material for batteries , current manufacturing processes are simply not scalable or commercially viable. The PUREVAPTMNSiR represents a game changing leap forward in resolving the issues of commercial viability and scalability, and with the Gen1 NSiR now operational, HPQ NANO is uniquely well positioned to offer industry participants a wide spectrum of products for testing.
The scale of the Gen1 PUREVAPTMNSiR allows HPQ NANO technical provider PyroGenesis to take full advantage of a quick R&D feedback loop during the testing phase. Over short periods, tests are completed, material produced is analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD), operational parameters are reviewed and system modifications and/or operational improvements are implemented. This is the key to our methodical approach of developing a truly disruptive low-cost technology that is going to change nano silicon materials manufacturing.
Tourillon added “HPQ’s Silicon R&D consortiumhasthe depth and flexibility to meet the challenges as we strive to produce products for renewable energy storage participants and electric vehicle manufacturers, who are searching for cost effective ways of increasing the Silicon contained in their batteries. Silicon’s potential to meet energy storage demand is undeniable, generatingmassive investments,and serious industry interest.We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Posted by AGORACOM-JC
at 8:07 AM on Thursday, January 21st, 2021
Updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.
Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.
TORONTO, Jan. 21, 2021– Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia. Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.
Initiation of pre-clinical studies on RHO Phyto in collaboration with University of Guelph
Further to Avicanna’s previous announcement regarding Dr. Khokhar’s research team at the University of Guelph being awarded a Natural Sciences and Engineering Research Council of Canada (“ NSERC ”) Alliance grant focused on the neurobiological underpinnings of cannabis toxicosis with the aim to evaluate Avicanna’s formulations in the treatment of cannabis-induced toxicosis, the project is now being expanded. The expansion of the project includes pharmacokinetic and behavioural testing of Avicanna’s RHO Phyto™ formulations as well as studying their efficacy in alleviating neuropathic pain and addiction. The data generated from the research will help guide Avicanna’s clinical development, including the pharmaceutical and real-world evidence studies related to the RHO Phyto formulations, and will provide additional information to health care practitioners who are recommending and prescribing the products in several markets.
COVID-19 drug candidate project update
The research collaboration with the University of Toronto on the development of a drug candidate to treat lung inflammation caused by COVID-19, with funding support from an NSERC Alliance grant and a MITACS Alliance grant, is complete. The peer-reviewed grants were focused on the development of a cannabinoid formulation to be used for further research on COVID-19. The physical and chemical characterization of the optimized cannabinoid formulation is complete, which included its stability and drug release properties in relevant conditions.
COVID-19 and anti-inflammatory related research collaboration with TRU with non-dilutive funding
In partnership with Avicanna, Dr. Kingsley Donkor and collaborators from Thompson Rivers University (” TRU ”), will be evaluating naturally derived cannabinoids and candidate formulations for their efficacy to modulate the receiving receptor of COVID-19 (angiotensin-converting ACE2 gene expression). This project will focus on elucidating the mechanism of action of novel prophylactic nasal and oral cannabinoid products for humans that target ACE2 viral gateways. Candidate formulations, once identified, will be evaluated for anti-inflammatory effects in human-derived lung tissue models. The research with TRU is supported by an NSERC grant and a MITACS Internship.
